A Phase II Study of H56:IC31 in Healthy Adolescents

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

June 30, 2021

Conditions
Tuberculosis Infection
Interventions
BIOLOGICAL

H56:IC31

The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.

OTHER

Placebo

Normal saline

Trial Locations (4)

1632

Aurum Institute - Tembisa, Tembisa

2571

Aurum Institute - Klerksdorp, Klerksdorp

0300

Aurum Institute - Rustenburg, Rustenburg

Unknown

National Institute for Medical Research, Mwanza

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Statens Serum Institut

OTHER

collaborator

Aurum Institute

OTHER

collaborator

South African Tuberculosis Vaccine Initiative

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

University of Bergen

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

lead

Aeras

OTHER